SDHA and neoplasm: Paclitaxel and shikonin showed a similar anti-tumor activity against (OVCAR3 cell lines +/− SDHA), however shikonin was significantly more potent in killing Caov3-SDHA cells than paclitaxel (Figure 8D,E and Supplementary Figure S5B–D).